Form 4: Atara Biotherapeutics EVP, Chief Regulatory Officer Jill Henrich Reports Sale of Common Stock
SEC Form 4 Filing
Jill Henrich, EVP, Chief Regulatory Officer of Atara Biotherapeutics, sold 1,059 shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 3, 2025, Jill Henrich, the EVP, Chief Regulatory Officer of Atara Biotherapeutics, sold 1,059 shares of common stock.
- The sale was executed at a price of $6.997 per share.
- The transaction was conducted to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
- Following the transaction, Henrich beneficially owns 18,679 shares of Atara Biotherapeutics stock, which includes 360 shares purchased under the Issuer's Employee Stock Purchase Plan on November 29, 2024.
Sentiment
Score: 5
Explanation: This is a routine transaction (Form 4 filing) related to stock compensation and tax obligations, and does not indicate a significant change in the company's outlook or insider sentiment.
Industry Context
Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| November 29, 2024 | 360 shares purchased under the Issuer's Employee Stock Purchase Plan |
| March 3, 2025 | Sale of 1,059 shares of common stock by Jill Henrich |
| March 5, 2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.